Detailed price information for Ivanhoe Mines Ltd (IVN-T) from The Globe and Mail including charting and trades.

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

At active dose levels (≥ 50 µg/kg), 26 of 33 evaluable patients (79%) achieved objective responses, including stringent or ...

Nottingham Forest will be playing in Europe next season after securing a spot in the UEFA Conference League. Qualifying for ...

The PSA progression free survival in Arm A was 2.6 months versus 2.5 months in Arm B, and radiologic progression free survival was 2.1 months and 1.9 months in arm A and B, respectively. The median ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also helped maintain red blood cell levels at acceptable levels, reduced ...

Sweden should phase out international adoptions, a government-appointed commission said on Monday, after an inquiry prompted ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...

United Launch Alliance's years-long delays with its new Vulcan rocket have flipped the script for national security missions, ...

Countless shadowed craters line the terminator all the way down to the moon's southern pole, while the 54-mile-wide (87 km) ...